Randomized, Double-Blind, Placebo-Controlled Trial if IL1-TRAP, Rilonacept, in Systemic Sclerosis -A Phase I/II Biomarker Trial
Phase of Trial: Phase I/II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Rilonacept (Primary)
- Indications Systemic scleroderma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 01 Dec 2017 Status changed from recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 29 Mar 2017 Planned End Date changed from 1 Jan 2017 to 1 Sep 2017.